allylamine has been researched along with Diabetes Mellitus, Type 2 in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (35.09) | 29.6817 |
| 2010's | 36 (63.16) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Esan, O; Viljoen, A; Wierzbicki, AS | 1 |
| Liu, J; Qian, C; St Peter, WL; Ye, X | 1 |
| Loke, SC; Ooi, CP | 2 |
| Chou, HS; Ford, DM; Rigby, SP; Rosenstock, J; Tao, B | 1 |
| Elkeles, RS | 1 |
| Chou, HS; Jones, MR; Rigby, SP; Rosenson, RS | 1 |
| Hansen, M; Knop, FK; Sonne, DP | 1 |
| Ford, DM; Gavin, JR; Jones, MR; Truitt, KE | 1 |
| Bloks, VW; Groen, AK; Kuipers, F | 1 |
| Al-Rasadi, K; Mikhailidis, DP; Rizzo, M | 1 |
| Dayer-Berenson, L; Finckenor, M | 1 |
| Brønden, A; Hansen, M; Knop, FK; Rohde, U; Sonne, DP; Vilsbøll, T | 1 |
| Baz-Hecht, M; Chou, HS; Ford, DM; Rosenstock, J; Tao, B; Truitt, KE | 1 |
| Fonseca, VA; Goldberg, RB; Jones, MR; Truitt, KE | 1 |
| Goldfine, AB | 1 |
| Bays, HE; Goldberg, RB; Jones, MR; Truitt, KE | 1 |
| Abby, SL; Jones, MR; Rosenson, RS | 1 |
| Marrs, JC | 2 |
| Gates, BJ; Levien, TL; Neumiller, JJ; Setter, SM; Sonnett, TE | 1 |
| Abby, SL; Jialal, I; Misir, S; Nagendran, S | 1 |
| Handelsman, Y | 3 |
| Fonseca, VA; Goldfine, AB | 1 |
| Staels, B | 1 |
| Abby, SL; Hernandez-Triana, E; Jin, X; Jones, MR; Lai, YL; Misir, S; Mudaliar, S; Nagendran, S; Unnikrishnan, AG | 1 |
| Bell, DS; O'Keefe, JH | 1 |
| Goldberg, RB | 1 |
| Fonseca, VA; Ford, DM; Goldfine, AB; Jones, MR; Truitt, KE; Wang, AC | 1 |
| Wright, WL | 1 |
| Abby, SL; Jones, MR; Lai, YL; Misir, S; Nagendran, S; Schwartz, SL; Xu, J | 1 |
| Fonseca, VA; Handelsman, Y; Staels, B | 1 |
| Jellinger, PS; Levy, P | 1 |
| Bloks, VW; Boverhof, R; Brufau, G; Jonkers, E; Kuipers, F; Murphy, EJ; Prado, K; Stellaard, F | 1 |
| Hagan, MA; Simons, WR | 1 |
| Levy, P | 1 |
| Ganda, OP | 1 |
| Avitabile, N; Banka, A; Fonseca, VA | 1 |
| Boudes, P; Viereck, C | 1 |
| Hofmann, AF | 1 |
| Bailey, CJ; Barnett, AH; Del Prato, S; Tahrani, AA | 1 |
| Brunetti, L; Campbell, RK | 1 |
| Aroda, VR; Chou, HS; Garvey, WT; Henry, RR; Jones, MR; Mudaliar, S | 1 |
| Aggarwal, S; Arora, RR; Loomba, RS | 1 |
| Beysen, C; Chan, M; Deines, K; Glass, A; Hellerstein, MK; Murphy, EJ; Protasio, J; Riiff, T; Tsang, E; Turner, SM | 1 |
| Holst, JJ; Liu, MK; Salen, G; Saumoy, M; Shang, Q; Xu, G | 1 |
| Davis, SN; Younk, LM | 1 |
| Handelsman, Y; Hernandez-Triana, E; Jones, MR; Misir, S; Nagendran, S; Rosenstock, J | 1 |
| Cobelli, C; Dalla Man, C; Law, JH; Piccinini, F; Rizza, RA; Sathananthan, M; Smushkin, G; Vella, A; Zinsmeister, AR | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
| Bailey, WL; Jones, MR; Kalin, MF; Schwartz, SL; Zieve, FJ | 1 |
| Bays, HE; Cohen, DE | 1 |
| Kuipers, F; Staels, B | 1 |
| Fonseca, VA; Jones, MR; Rosenstock, J; Truitt, KE; Wang, AC | 1 |
| Brinton, EA | 1 |
28 review(s) available for allylamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Randomized Controlled Trials as Topic | 2014 |
Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Randomized Controlled Trials as Topic | 2014 |
Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion.
Topics: Allylamine; Animals; Bile Acids and Salts; Blood Glucose; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Energy Metabolism; Fibroblast Growth Factors; Glucagon-Like Peptide 1; Humans; Lipid Metabolism; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled | 2014 |
Beyond intestinal soap--bile acids in metabolic control.
Topics: Allylamine; Animals; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Energy Metabolism; Fibroblast Growth Factors; Glycated Hemoglobin; Humans; Insulin Resistance; Lipid Metabolism; Male; Mice; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Signal Transduction | 2014 |
Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypercholesterolemia; Lipids; Suspensions; Tablets | 2014 |
Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.
Topics: Allylamine; Anticholesteremic Agents; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hypoglycemic Agents; Polyamines; Sevelamer; Treatment Outcome; Triglycerides | 2015 |
Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway.
Topics: Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Risk Factors | 2008 |
Colesevelam for the management of type 2 diabetes.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Cholesterol; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Humans; Hyperglycemia | 2009 |
Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus.
Topics: Adult; Allylamine; Anticholesteremic Agents; Clinical Trials as Topic; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents | 2009 |
The use of colesevelam HCl in patients with type 2 diabetes mellitus: combining glucose- and lipid-lowering effects.
Topics: Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; United States | 2009 |
The role of colesevelam HCl in type 2 diabetes mellitus therapy.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypercholesterolemia; Life Style; Patient Education as Topic; Primary Prevention; United States | 2009 |
A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus.
Topics: Allylamine; Animals; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypercholesterolemia; United States | 2009 |
Rediscovering bile acid sequestrants.
Topics: Allylamine; Anticholesteremic Agents; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fluorobenzenes; Humans; Hypoglycemic Agents; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.
Topics: Adult; Allylamine; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Humans; Lipids; Male | 2010 |
The potential role of colesevelam in the management of prediabetes and type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Allylamine; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Practice Guidelines as Topic; Prediabetic State; Prognosis; Severity of Illness Index; Treatment Outcome | 2010 |
Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus.
Topics: Adult; Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dyslipidemias; Humans | 2010 |
The role of bile acid sequestrants in the management of type 2 diabetes mellitus.
Topics: Adult; Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Cardiovascular Diseases; Clinical Trials as Topic; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Humans | 2010 |
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Topics: Adult; Allylamine; Animals; Anticholesteremic Agents; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Randomized Controlled Trials as Topic | 2011 |
Role of bile acid sequestrants in the treatment of type 2 diabetes.
Topics: Allylamine; Bile Acids and Salts; Cholestyramine Resin; Colesevelam Hydrochloride; Colestipol; Diabetes Mellitus, Type 2; Epichlorohydrin; Hypolipidemic Agents; Imidazoles; Resins, Synthetic | 2011 |
Management of type 2 diabetes: new and future developments in treatment.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Allylamine; Anticholesteremic Agents; Bariatric Surgery; Bile Acids and Salts; Cardiovascular System; Colesevelam Hydrochloride; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucokinase; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liver; Obesity; Peptides; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Venoms | 2011 |
Clinical efficacy of colesevelam in type 2 diabetes mellitus.
Topics: Allylamine; Anticholesteremic Agents; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic | 2011 |
Efficacy of colesevelam on lowering glycemia and lipids.
Topics: Allylamine; Animals; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypercholesterolemia; Triglycerides | 2012 |
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; Cholagogues and Choleretics; Cholesterol, LDL; Colesevelam Hydrochloride; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Interactions; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Triglycerides | 2012 |
Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.
Topics: Aged; Allylamine; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypoglycemic Agents; Medication Adherence | 2012 |
Colesevelam for type 2 diabetes mellitus.
Topics: Allylamine; Blood Glucose; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic | 2012 |
Colesevelam: a new and improved bile acid sequestrant?
Topics: Allylamine; Anticholesteremic Agents; Bile Acids and Salts; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia | 2013 |
Bile acid sequestrants and the treatment of type 2 diabetes mellitus.
Topics: Allylamine; Animals; Bile Acids and Salts; Cholestyramine Resin; Clinical Trials as Topic; Colesevelam Hydrochloride; Colestipol; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Glucose; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Lipid Metabolism; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2007 |
Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation.
Topics: Allylamine; Animals; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Carrier Proteins; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Membrane Glycoproteins | 2008 |
18 trial(s) available for allylamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The glucose and lipid effects of colesevelam as monotherapy in drug-naïve type 2 diabetes.
Topics: Adult; Aged; Allylamine; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged | 2014 |
Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.
Topics: Adult; Allylamine; Anticholesteremic Agents; Chylomicrons; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Least-Squares Analysis; Lipoproteins; Male | 2014 |
Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.
Topics: Allylamine; Blood Glucose; Colesevelam Hydrochloride; Demography; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Least-Squares Analysis; Lipids; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones; Treatment Outcome | 2014 |
Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypoglycemic Agents; Insulin; Male; Mexico; Middle Aged; Prospective Studies; Treatment Outcome; United States | 2008 |
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Blood Glucose; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Retrospective Studies; Treatment Outcome | 2008 |
Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes.
Topics: Aged; Allylamine; Anticholesteremic Agents; Biomarkers; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Metformin; Middle Aged; Particle Size; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2009 |
Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis.
Topics: Aged; Allylamine; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sulfonylurea Compounds | 2009 |
Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
Topics: Adolescent; Adult; Aged; Algorithms; Allylamine; Anticholesteremic Agents; Clinical Trials as Topic; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Prediabetic State; Research Design; Young Adult | 2009 |
Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes.
Topics: Aged; Allylamine; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2010 |
The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study.
Topics: Adult; Aged; Algorithms; Allylamine; Anticholesteremic Agents; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Pilot Projects; Placebos; Postprandial Period | 2010 |
Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism.
Topics: Adult; Allylamine; Bile Acids and Salts; Blood Glucose; Cholic Acid; Colesevelam Hydrochloride; Deoxycholic Acid; Diabetes Mellitus, Type 2; Fibroblast Growth Factors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Signal Transduction | 2010 |
Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Sulfonylurea Compounds; United States; Young Adult | 2012 |
Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
Topics: Administration, Oral; Adult; Aged; Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Cholesterol; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycated Hemoglobin; Humans; Insulin; Kinetics; Lipid Metabolism; Lipogenesis; Liver; Male; Middle Aged; Placebos; Postprandial Period | 2012 |
Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes.
Topics: Allylamine; Anticholesteremic Agents; Cholesterol; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Lipoproteins; Male; Metformin; Treatment Outcome | 2012 |
The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; C-Peptide; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Postprandial Period | 2013 |
Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
Topics: Aged; Allylamine; Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Cholesterol; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Gastrointestinal Diseases; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Pilot Projects | 2007 |
Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose; Humans; Male; Middle Aged; Program Development; Receptors, Cytoplasmic and Nuclear | 2007 |
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
Topics: Adult; Aged; Allylamine; Anticholesteremic Agents; Blood Glucose; Body Mass Index; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sulfonylurea Compounds | 2008 |
11 other study(ies) available for allylamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Colesevelam - a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia.
Topics: Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Hyperlipidemias; Hypolipidemic Agents; Triglycerides | 2022 |
Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.
Topics: Age Factors; Aged; Allylamine; Anticholesteremic Agents; Cohort Studies; Colesevelam Hydrochloride; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hospitalization; Humans; Hyperlipidemias; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors; Sex Factors; Stroke; Treatment Outcome | 2013 |
Safety and efficacy of colesevelam HCl in the treatment of elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Allylamine; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic | 2014 |
The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?
Topics: Allylamine; Anticholesteremic Agents; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Female; Humans; Lipoproteins; Male | 2014 |
The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction.
Topics: Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Blood Glucose; Centers for Disease Control and Prevention, U.S.; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypercholesterolemia; United States | 2009 |
A new use for an old drug provides dual glucose and LDL-lowering therapy in the modern setting of T2D management: colesevelam HCL.
Topics: Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Cardiotonic Agents; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2009 |
The management of type 2 diabetes mellitus: a novel approach for addressing glycemic and lipid control with colesevelam HCl.
Topics: Allylamine; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Life Style; Practice Guidelines as Topic; Risk Reduction Behavior; Treatment Outcome; United States | 2009 |
An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
Topics: Adult; Aged; Allylamine; Cardiovascular Diseases; Cholesterol, LDL; Colesevelam Hydrochloride; Cost-Benefit Analysis; Databases, Factual; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypercholesterolemia; Insulin; Male; Metformin; Middle Aged; Models, Economic; Randomized Controlled Trials as Topic; Risk; Sulfonylurea Compounds; Treatment Outcome; United States | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release.
Topics: Allylamine; Anticholesteremic Agents; Blood Glucose; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans | 2011 |
The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
Topics: Allylamine; Animals; Anticholesteremic Agents; Apoptosis; Bile Acids and Salts; Blood Glucose; Body Weight; Cell Proliferation; Cell Size; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Diet; Drug Synergism; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Male; Postprandial Period; Pyrazines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; RNA, Messenger; Sitagliptin Phosphate; Triazoles | 2012 |